2 Healthcare Stocks to Buy Before They Get Bought Out

Abivax - Abivax is developing obefazimod, a potential blockbuster therapy for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis and phase 2b trials for Crohn's disease [2][3] - The ulcerative colitis market is projected to grow from $8.7 billion in 2026 to $14.3 billion by 2035, indicating significant market potential for obefazimod [4] - Abivax has seen a share price increase of over 1,900% in the past year, driven by positive clinical trial results and rumors of potential buyout interest from companies like Eli Lilly and AstraZeneca [6] - The company reported €589.7 million (approximately $697 million) in cash and equivalents, sufficient to fund operations into Q4 2027 [8] Nektar Therapeutics - Nektar's lead candidate, rezpegaldesleukin, has shown promising results in phase 2b trials for moderate-to-severe atopic dermatitis, with over 80% of patients achieving significant skin improvement [10] - The drug is also being tested for multiple indications, including alopecia areata, type 1 diabetes, and multiple sclerosis, enhancing its potential as a "pipeline-in-a-drug" [11] - Following a $460 million capital raise, Nektar has over $700 million in liquidity, allowing it to fund operations into 2027, with analysts projecting significant upside in stock price [12] - Nektar is considered a potential acquisition target for larger pharmaceutical companies, including Sanofi and AbbVie, which could see strategic value in its pipeline [13]